Board of Directors
The Photosoft™ technology
Invion appoints cancer experts to Scientific Advisory Board
Invion Collaborates to Develop Powerful Skin Cancer Gel
Invion spin-off Chronic Airway Therapeutics selects leading CRO for the future development of nadolol
Invion is a clinical-stage life-sciences company that is leading the global clinical development of the Photosoft™ technology for the treatment of cancers.
Invion has an alliance with leading Australian medical research institute, Hudson Institute of Medical Research. Listen to Dr Andrew Stephens talk about the Hudson's work with Invion.
Developing PDT for the treatment of cancers
PDT is a clinically approved, minimally invasive therapeutic treatment that uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system.